Cargando…
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q con...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420622/ https://www.ncbi.nlm.nih.gov/pubmed/34260717 http://dx.doi.org/10.1093/infdis/jiab368 |
_version_ | 1783748924311339008 |
---|---|
author | Ferreira, Isabella A T M Kemp, Steven A Datir, Rawlings Saito, Akatsuki Meng, Bo Rakshit, Partha Takaori-Kondo, Akifumi Kosugi, Yusuke Uriu, Keiya Kimura, Izumi Shirakawa, Kotaro Abdullahi, Adam Agarwal, Anurag Ozono, Seiya Tokunaga, Kenzo Sato, Kei Gupta, Ravindra K |
author_facet | Ferreira, Isabella A T M Kemp, Steven A Datir, Rawlings Saito, Akatsuki Meng, Bo Rakshit, Partha Takaori-Kondo, Akifumi Kosugi, Yusuke Uriu, Keiya Kimura, Izumi Shirakawa, Kotaro Abdullahi, Adam Agarwal, Anurag Ozono, Seiya Tokunaga, Kenzo Sato, Kei Gupta, Ravindra K |
author_sort | Ferreira, Isabella A T M |
collection | PubMed |
description | The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity. |
format | Online Article Text |
id | pubmed-8420622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84206222021-09-10 SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion Ferreira, Isabella A T M Kemp, Steven A Datir, Rawlings Saito, Akatsuki Meng, Bo Rakshit, Partha Takaori-Kondo, Akifumi Kosugi, Yusuke Uriu, Keiya Kimura, Izumi Shirakawa, Kotaro Abdullahi, Adam Agarwal, Anurag Ozono, Seiya Tokunaga, Kenzo Sato, Kei Gupta, Ravindra K J Infect Dis Major Articles and Brief Reports The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity. Oxford University Press 2021-09-09 /pmc/articles/PMC8420622/ /pubmed/34260717 http://dx.doi.org/10.1093/infdis/jiab368 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Major Articles and Brief Reports Ferreira, Isabella A T M Kemp, Steven A Datir, Rawlings Saito, Akatsuki Meng, Bo Rakshit, Partha Takaori-Kondo, Akifumi Kosugi, Yusuke Uriu, Keiya Kimura, Izumi Shirakawa, Kotaro Abdullahi, Adam Agarwal, Anurag Ozono, Seiya Tokunaga, Kenzo Sato, Kei Gupta, Ravindra K SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion |
title | SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion |
title_full | SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion |
title_fullStr | SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion |
title_full_unstemmed | SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion |
title_short | SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion |
title_sort | sars-cov-2 b.1.617 mutations l452r and e484q are not synergistic for antibody evasion |
topic | Major Articles and Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420622/ https://www.ncbi.nlm.nih.gov/pubmed/34260717 http://dx.doi.org/10.1093/infdis/jiab368 |
work_keys_str_mv | AT ferreiraisabellaatm sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT kempstevena sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT datirrawlings sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT saitoakatsuki sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT mengbo sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT rakshitpartha sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT takaorikondoakifumi sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT kosugiyusuke sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT uriukeiya sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT kimuraizumi sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT shirakawakotaro sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT abdullahiadam sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT agarwalanurag sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT ozonoseiya sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT tokunagakenzo sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT satokei sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT guptaravindrak sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion AT sarscov2b1617mutationsl452rande484qarenotsynergisticforantibodyevasion |